Opinion|Videos|November 20, 2024
Disease Progression and Extrahepatic Manifestations of PBC
Key Takeaways
- Vitamin deficiencies, especially fat-soluble ones, are prevalent in PBC due to malabsorption issues.
- Osteoporosis is a major concern in PBC, often linked to chronic cholestasis and vitamin D deficiency.
The panel of experts examine major complications and comorbidities associated with primary biliary cholangitis (PBC), including vitamin deficiencies, osteoporosis, and conditions like metabolic-associated steatohepatitis (MASH), autoimmune disorders, and obesity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some major complications and comorbidities associated with PBC (eg, vitamin deficiency, osteoporosis, comorbid conditions such as MASH, autoimmune conditions, obesity)?
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH
5